

## Index

- (+)-*Desmethyl-sibutramine*, 1193  
 (+)-*Didesmethyl-sibutramine*, 1193  
 (+)-*N-Desmethylzopiclone*, 1055  
 (R)-*Oxaprotiline*, 1068  
 (R)-*Tofisopam*, 1064  
 (R)-*Zacopride*, 1061  
 (S)-*Tofisopam*, 1055  
 163090, 1056  
 2-hydroxyimipramine, 176  
 31264-RP, 1065  
 3-2,4 dimethoxy benylidene, 429  
 597599, 1063  
 5-HT<sub>1A</sub> antagonists, 116, 117, 250  
 5-HT<sub>2A</sub> antagonists, 117, 493, 553  
 5-HT<sub>2C</sub> antagonists, 118, 120  
 5-HT<sub>2C</sub> ligands, 120  
 5-HT<sub>6</sub> ligands, 122, 123  
 5-HT<sub>7</sub> ligands, 120, 121  
 644784, 580, 582  
 A-77000, 1067  
 Abaperidone, 579, 581  
 ABT-089, 1192, 1193  
 AC-5216, 251, 1062  
 ACP-103, 429, 580, 583  
 ACPC, 250, 253  
 ACR-16, 579, 582  
 Adatanserin, 1059  
 ADD, 1091, 1130, See ADHD  
**ADHD**, 176, 181, 392, 733, 1091, 1092, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1105, 1106, 1107, 1108, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1155, 1156, 1160, 1161, 1163, 1164, 1165, 1166, 1167, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1183, 1184, 1185, 1187, 1189, 1192  
 Adult cases, 1124, 1125, 1127  
 Classification, 1092  
 Comorbidity, 1110, 1111  
 Costs, 1112  
 Definition, 1091, 1105, 1106, 1107, 1108  
 Diagnosis, 1099, 1127, 1128, 1129, 1130, 1132  
 Epidemiology, 1108, 1110  
 Etiology, 1095, 1114  
   Environment, 1095, 1115, 1116, 1117, 1118  
   Genetics, 1096, 1097, 1098, 1114, 1115, 1158, 1159, 1161, 1164, 1167, 1168, 1171, 1174, 1175  
 Neurobiology, 1155, 1156  
 Neurochemistry, 1156  
   Dopamine, 1157, 1158, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1175  
   Noradrenaline, 1168, 1169, 1170, 1171, 1172, 1173  
   Serotonin, 1173, 1174  
   SNAP-25, 1175, 1176  
 Pathophysiology, 1118  
   Electrophysiology, 1121  
   Executive functions, 1118  
   Neuroimaging, 1119, 1120  
 Symptoms, 1122, 1123, 1124  
 Treatment, 1133  
   Behavioral therapy, 1142, 1143

*Antidepressants, Antipsychotics, Anxiolytics*

Edited by H. Buschmann, J. L. Dias, J. Holenz, A. Párraga, A. Torrens, and J. M. Vela  
 Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim  
 ISBN: 978-3-527-31058-6

- Multimodal treatment programs*, 1144
- Non-stimulants*, 1138, 1139, 1140, 1141, 1142
- Psychostimulants*, 1134, 1135, 1136, 1137, 1176
- Adinazolam*, 251, 1066
- ADX-10059*, 1056
- AFQ-056*, 1056
- AFX-221*, 1192
- AGN-2979*, 1060
- Agomelatine*, 129, 252, 261
- Agoraphobia*, 620, 621, 624, 646, 807, 881, 884, 888
- Ainazolam*, 260
- Alnespirone*, 250, 255, 1060
- Alprazolam**, 77, 89, 951, 953
  - Synthesis*, 951, 952, 953
  - Use, PK and Metabolism*, 953
- Amantadine*, 98
- Amarin*, 130, 249, 251
- Amibegron*, 1068
- Amineptine**, 79, 192, 193
  - Synthesis*, 193
  - Use, PK and Metabolism*, 193
- Aminoglutetimide*, 97
- Amisulpride**, 377, 403, 423, 491, 493, 577, 578
  - Synthesis*, 577
  - Use, PK and Metabolism*, 578
- Amitriptyline**, 74, 75, 79, 113, 174, 181, 185
  - Synthesis*, 174
  - Use, PK and Metabolism*, 174
- Amoxapine**, 79, 190, 191
  - Synthesis*, 190
  - Use, PK and Metabolism*, 190
- Ampakine*, 251
- Animal models**
  - Construct validity*, 144, 450, 924
  - Ecological validity*, 924
  - Etiological validity*, 924
  - Face validity*, 143, 924
  - Genetic validity*, 924
  - Predictive validity*, 143, 450, 924
  - Reliability*, 450, 924
- Animal models of anxiety**, 669, 762, 926, 937
  - Conditioned*
    - Conflict tests*, 935
    - Fear potentiated startle*, 934
    - Shock-induced freezing*, 934
    - Shock-induced ultrasonic vocalizations*, 936
    - Shock-probe burying*, 935
  - Drug abuse*, 693
  - Implication for drug discovery*, 940
  - Unconditioned*
    - Elevated plus maze*, 930
    - Hole board*, 932
    - Light/dark transitions*, 929
    - Mouse defense test battery*, 933
    - Novelty-suppressed feeding task*, 933
    - Open field paradigm*, 928
    - Social interaction*, 931
    - Zero plus maze*, 930
- Animal models of depression**, 145
  - Chronic mild stress*, 148
  - Chronic severe stress*, 148
  - Conditioned place preference*, 156
  - Forced swimming test*, 151
  - Genetic models*, 158
  - Intracranial self-stimulation*, 154
  - Learned helplessness*, 146
  - Olfactory bulbectomy*, 145
  - Social loss and deprivation*, 156
  - Sucrose preference*, 155
  - Tail suspension test*, 152
  - Water despair*, 151
  - Withdrawal from psychostimulants*, 150

**Animal models of schizophrenia, 450**

Complexity, 449, 450

Genetic models, 468

Dopaminergic system, 471

Glutamatergic system, 470

Others, 472

Neurodevelopmental models, 464

Disruption of neurogenesis, 467

Neonatal hippocampal lesion, 465

Perinatal infection, 468

Perinatal malnutrition, 468

Pharmacological models, 453

Dopaminergic agonists, 459

NMDA/glutamate antagonists, 453

Serotonergic agents, 461

ANPH-102, 1063

Anticonvulsivants, 97

**Antidepressants, 22, 68, 73, 87, 88, 129, 906, 909, 1006, 1138, 1189**

Basic aspects, 69, 111

Diversity, 73, 112

Efficacy, 71

Information to the patient, 70

Interactions, 76

Maintenance therapy, 71

Mechanism of action, 68

Response-predicting factors, 93

Side-effects, 74

Treatment combination, 99

Treatment optimization, 95

Treatment potentiation, 95

Treatment switching, 99

Treatment-resistant, 94

Withdrawal, 72

**Antipsychotics, 375, 389**

Basic aspects, 375, 389

CB<sub>1</sub> antagonists, 428D<sub>2</sub>/D<sub>3</sub> only hypothesis, 423D<sub>4</sub> antagonists, 427

Glutamatergic neurotransmission, 425

Muscarinic/nicotinic receptors, 428

NK<sub>3</sub> antagonists, 427

Non-pharmacological treatment, 377

NTS1 antagonists, 428

Rapid dissociation, 422

Role of D<sub>2</sub> partial agonism, 424**Anxiety**

Agoraphobia, 620, 624, 646

Anatomy of obsessive-compulsive disorder, 726, 732

Benzodiazepines in posttraumatic stress disorder, 714

Biochemistry of obsessive-compulsive disorder, 725

Catecholamines in posttraumatic stress disorder, 710

Childhood anxiety, 637, 657

Cholecystokinin and memory, 850

Cholecystokinin in panic disorder, 723

Classification, 619, 881

Cognition in childhood anxiety, 776

Diagnosis

Generalized anxiety disorder, 887

Obsessive-compulsive disorder, 891

Panic disorder, 884

Social phobia, 889

Specific phobia, 890

Drug abuse and animal models, 693

Drug abuse and anxiety, 685

Generalized anxiety disorder, 692

Genetics, 696

Neurobehavioral mechanisms, 697

Obsessive-compulsive disorder, 691

Panic disorder, 685

Personality traits, 695

Posttraumatic stress disorder, 687

Social phobia, 689

Early stress in childhood anxiety, 769

- Electroencephalography in generalized anxiety disorders*, 783
- Epidemiology*, 645
- Agoraphobia*, 646
  - Childhood anxiety*, 657
  - Generalized anxiety disorder*, 651, 886
  - Mixed anxiety–depressive disorder*, 655
  - Obsessive–compulsive disorder*, 652, 890
  - Panic disorder*, 646, 882
  - Posttraumatic stress disorder*, 653
  - Social phobia*, 648, 888
  - Specific phobia*, 650, 889
- Etiology*, 667
- Environment and genetics*, 676
  - Generalized anxiety disorder*, 886
  - Genetics*, 673, 674, 675
  - Obsessive–compulsive disorder*, 890
  - Panic disorder*, 883
  - Specific phobia*, 890
  - Stress*, 667
  - Stress and HPA*, 668, 669, 671
- GABA-Benzodiazepines in panic disorder*, 722
- GABAergic and cholinergic interactions*, 853
- Generalized anxiety disorder*, 628, 651, 692, 885, 886, 887
- Genetics*, 673, 674, 696
- Glutamate and memory*, 852
- Hippocampal dissociations*, 855
- HPA axis in posttraumatic stress disorder*, 711
- Individual differences*, 860
- Management*
- Generalized anxiety disorder*, 887
  - Obsessive–compulsive disorder*, 892
  - Panic disorder*, 885
  - Social phobia*, 889
  - Specific phobia*, 890
- Maltreatment in childhood anxiety*, 769
  - Memory bias*, 808
  - Memory bias in generalized anxiety disorder*, 817
  - Memory bias in obsessive–compulsive disorder*, 814
  - Memory bias in panic disorder*, 810
  - Memory bias in posttraumatic stress disorder*, 816
  - Memory bias in social phobia*, 812
  - Memory disturbances*, 819
  - Memory processes*, 807
  - Mixed anxiety–depressive disorder*, 636, 655
  - Neurobiology of anxiety–depression disorder*, 784
  - Neurobiology of childhood anxiety*, 761, 762, 767, 768, 769, 775, 776
  - Neurobiology of generalized anxiety disorder*, 777
  - Neurobiology of generalized anxiety disorders*, 778, 782, 783
  - Neurobiology of obsessive–compulsive disorder*, 725, 726, 728, 732
  - Neurobiology of panic disorder*, 717, 718, 719, 720, 721, 722, 723
  - Neurobiology of posttraumatic stress disorder*, 709, 710, 711, 713, 714, 715
  - Neurobiology of social phobia*, 734, 735, 739, 740, 742
  - Neurochemistry of childhood anxiety*, 762, 767, 768
  - Neurochemistry of generalized anxiety disorders*, 778
  - Neurochemistry of panic disorder*, 718
  - Neuroendocrinology and neurochemistry of social phobia*, 735
  - Neuroimaging in generalized anxiety disorders*, 782
  - Neuroimaging in panic disorder*, 723
  - Neuroimaging in posttraumatic stress disorder*, 715
  - Neuroimaging in social phobia*, 739
  - Neuronal plasticity*, 857

- Neuropsychology of obsessive–compulsive disorder*, 728  
*Neuropsychology of social phobia*, 740  
*Neuropsychology of posttraumatic stress disorder*, 715  
*Noradrenaline in panic disorder*, 719, 721  
*Obsessive–compulsive disorder*, 630, 652, 691, 890, 891, 892  
*Panic attack*, 619, 882  
*Panic disorder*, 622, 646, 685, 882, 883, 884, 885  
*Posttraumatic stress disorder*, 633, 653, 671, 687  
*Prefrontal cortex*, 847, 856  
*Serotonin in panic disorder*, 720, 721  
*Serotonin in posttraumatic stress disorder*, 713  
*Sex differences*, 862  
*Sex differences in childhood anxiety*, 775  
*Social costs*, 658  
*Social phobia*, 626, 648, 689, 888, 889  
*Specific phobia*, 625, 650, 889, 890  
*Stress response*, 667, 668, 669, 856, 857, 860, 862  
**Treatment**  
     5-HT<sub>1A</sub> agonists, 900, 904  
     Antidepressants, 897, 902, 909, 911, 914  
     Benzodiazepines, 899, 903, 907, 910, 912  
     Generalized anxiety disorder, 902, 903, 904  
     Obsessive–compulsive disorder, 914  
     Overview, 896  
     Panic disorder, 908, 909, 910  
     Posttraumatic stress disorder, 911, 912, 913  
     Prevention of posttraumatic symptoms, 913  
*Social phobia*, 905, 907  
*Specific phobia*, 908  
*Working memory*, 847  
*AP-521*, 1060  
**Aripiprazole**, 377, 403, 404, 424, 491, 493, 571, 572, 1163  
     Synthesis, 572  
     Use, PK and Metabolism, 572  
*Artofisopam*, 1064  
*Asenapine*, 250, 259, 429, 579, 585  
**Atomoxetine**, 1141, 1142, 1183, 1189  
     Synthesis, 1189, 1190  
     Use, PK and Metabolism, 1189  
*Attention deficit hyperactivity disorder*. See ADHD  
*Atypical antidepressants*, 112, 116  
**Atypical antipsychotics**, 96, 401, 403, 493, 549, 553, 577  
     5-HT<sub>2A/D2</sub> hypothesis, 403  
     Role of 5-HT<sub>1A</sub>, 409  
     Role of 5-HT<sub>2C</sub>, 414  
     Role of 5-HT<sub>6</sub>/5-HT<sub>7</sub>, 416  
     Role of  $\alpha_1$ -adrenoceptor, 417  
     Role of  $\alpha_2$ -adrenoceptor, 420  
*AV-608*, 1061  
*AVE-1625*, 580, 584  
*Azamianserin*. See Mirtazapine  
*Basolateral amygdala*, 843  
*Bay-q-7821*, 1066, 1067  
*Befetupitant*, 1063  
**Benperidol**, 491, 492, 522  
     Synthesis, 522  
     Use, PK and Metabolism, 522  
**Benzodiazepines**, 88, 896, 900, 904, 917, 933, 934, 936, 951, 961, 1061, 1064  
     Adverse events, 89  
     Interactions, 90  
     Management, 90  
     Overdose, 90  
     Pharmacokinetics, 89  
     Risk of dependence, 90  
*Bifeprunox*, 250, 259, 403, 429, 580, 585  
*Binspirone*, 1052

- Bipolar disorder*, 3, 9
- Bis(olanzapine)*, 579, 585
- BL-1020*, 580, 582
- BLA, XXXIII*, 835, 836, 837, 839, 840, 841, 842, 843, 844, 846, 847, 848, 852, See *Basolateral amygdala*
- Blonanserin*, 579, 586
- BMS-562086*, 250, 255
- BMY-13805*, 1065
- Bretazenil*, 1066
- BRL-46470*, 1058
- BRL-46470A*, 1060
- Brofaromine*, 251, 259
- Bromantan*, 1062
- Bromantane*, 1062
- Bromazepam**, 89, 985, 987
- Synthesis*, 986, 987, 988
- Use*, 987
- Bromocryptine*, 98
- Bromperidol**, 491, 492, 541
- Synthesis*, 541
- Use, PK and Metabolism*, 541
- Brotizolam**, 970, 973
- Synthesis*, 970, 971, 972
- Use and PK*, 973
- BTG-1501*, 1060
- BTG-1640*, 1053
- Bupropion**, 242, 243, 1139
- Synthesis*, 242
- Use, PK and Metabolism*, 243
- Buspirone**, 98, 900, 904, 917, 1002, 1003
- Synthesis*, 1002
- Use, PK and Metabolism*, 1003
- Butriptyline**, 180
- Synthesis*, 180
- Use*, 180
- CAM-958*, 1060
- Cannabidiol*, 580, 584
- Carbamazepin**, 240
- Synthesis*, 240
- Use, PK and Metabolism*, 241
- Carnosine*, 580, 584
- Carpipramine**, 491, 492, 537, 1019, 1020
- Synthesis*, 537, 1019, 1020
- Use and PK*, 1020
- Use, PK and Metabolism*, 537
- Casopitant*, 130, 251, 256, 1064
- Catatonic schizophrenia*, 301, 366
- CCK*, 723, 778, 781, 782, 850, 851, 852, See *Cholecystokinin*
- CGP-12103A*, 1068
- CGP-361A*, 1051
- CGP-608*, 1061
- CGS-15040A*, 1059
- CGS-19480A*, 1051
- CGS-19755*, 1067
- CGS-20625*, 1058
- CGS-8216*, 1051
- Chlordiazepoxide**, 89, 976, 977
- Synthesis*, 976
- Use, PK and Metabolism*, 977
- Chlorpromazine**, 376, 396, 491, 492, 495, 496, 1013, 1015
- Synthesis*, 496
- Use, PK and Metabolism*, 496
- Chlorprothixene*, 397, 491
- Cholecystokinin*, 723, 850
- CI-1043*, 1068
- CI-988*, 723, 782, 1060
- Cianopramine*, 258
- Cipralisant*, 1192, 1193
- Citalopram**, 74, 75, 114, 200, 201, 202
- Synthesis*, 200
- Use, PK and Metabolism*, 201
- CL-216303*, 1064
- Classic antipsychotics**, 498, See *Typical antipsychotics*

- Clobazam**, 89, 988  
Metabolism, 988, 990  
Synthesis, 988, 989
- Clomipramine**, 74, 75, 113, 184, 185, 186, 917, 1043  
Synthesis, 184, 1043, 1044  
Use, PK and Metabolism, 185
- Clonazepam**, 907, 954  
Synthesis, 954, 955
- Clorazepate**, 995  
Synthesis, 995, 996  
Use, PK and Metabolism, 995
- Clorazepate, 995
- Clorgyline, 259
- Clotiazepam**, 996, 998  
Synthesis, 996, 997  
Use and PK, 998
- Clotiazepam, 996
- Clovoxamine, 251, 260
- Clozapine**, 377, 402, 403, 404, 417, 422, 491, 493, 549, 550, 1162  
Synthesis, 550  
Use, PK and Metabolism, 550
- CP-122721, 251, 256
- CP-143867, 1053
- CP-316311, 250, 255
- CP-409092, 1053
- CP-93393, 1068
- CP-93393-1, 1068
- CR-2945, 1054
- CRD-101, 581, 582
- CRF, XXXII, XLV, 23, 24, 26, 27, 67, 123, 124, 668, 669, 670, 672, 698, 699, 700, 713, 737, 762, 763, 764, 766, 767, 768, 778, 782
- CRF Antagonists, 123
- CX-516, 251, 257, 426
- CX-717, 1192, 1194
- Cyamemazine**, 491, 492, 532, 534, 1020  
Synthesis, 532, 1021  
Use, 532
- Cyclobenzaprine**, 1044  
Synthesis, 1045, 1046, 1047
- D-13112, 1066
- Delucemine, 130, 251, 254
- Depression**  
Biochemistry, 63  
Classification, 52  
Cronobiological hypothesis, 27  
Epidemiology, 61  
Etiology, 7, 10  
Genetics, 10  
Infectious hypothesis, 28  
Introduction, 3, 51  
Management, 90  
Monoamine hypothesis, 14, 64  
Neuroendocrine hypothesis, 23, 66  
Neuroendocrinology, 66  
Neuroimaging, 29  
Neuropathology, 309  
Neurophysiology, 29  
Neuroplasticity, 31  
Non-pharmacological treatment, 100  
Pathogenesis, 14  
Physiopathology, 63  
Prevalence, 6  
Sleep, 27
- Desipramine**, 77, 79, 113, 176, 181  
Synthesis, 181  
Use, PK and Metabolism, 181
- Destroamphetamine, 1183
- Desvenlafaxine, 252, 261, 1069
- Dextofisopam, 1064
- Dextroamphetamine**, 97, 1136, 1183, 1184  
Synthesis, 1183  
Use and PK, 1184

- Diazepam**, 77, 89, 954, 956, 959, 961  
    *Metabolism*, 961  
    *Synthesis*, 956, 957, 959, 960  
    *Use and PK*, 961
- Dibenzepine*, 248
- Dihydroepiandrosterone*, 97
- Dilopetine*, 1062
- Dimetacrine*, 248
- Divalproex**, 243  
    *Synthesis*, 243  
    *Use PK and Metabolism*, 244
- Divaplon*, 1058
- DMP-904*, 250, 253
- DMXB-Anabaseine*, 580, 584
- DN-2327*, 1067
- dopamine reuptake inhibition*, 119
- Dosulepin**, 183  
    *Synthesis*, 183  
    *Use, PK and Metabolism*, 183
- DOV-102677*, 249, 252, 1193
- DOV-216303*, 249, 255, 1064
- DOV-21947*, 249, 252
- Doxepin**, 113, 187  
    *Synthesis*, 187  
    *Use, PK and Metabolism*, 188
- DP-VPA*, 251, 256
- Droperidol**, 491, 492, 517, 518  
    *Synthesis*, 518  
    *Use and PK*, 518
- Droperidole*, 397
- DU-125530*, 250, 254
- DU-13811*, 260
- DU-29373*, 1067
- Duloxetine**, 74, 86, 225, 226, 228  
    *Synthesis*, 225  
    *Use, PK and Metabolism*, 226
- DVS-233*, 129, 1069
- Dysthymic disorder**, 3, 8  
    *Classification*, 60  
    *Combined treatment*, 103  
    *Epidemiology*, 63  
    *Introduction*, 8  
    *Pharmacological treatment*, 101, 102  
    *Psychosocial treatment*, 103
- E-4424*, 1059
- E-6006*, 251, 253, 1062
- E-6039*, 251, 253, 1062
- Ebaltozan*, 1053
- EGIS-5810*, 1058
- EGIS-6775*, 1051
- Eglumegad*, 1061
- ELB-139*, 1062
- Electroconvulsive therapy*, 100
- Elzasonan*, 130, 250, 255
- Emapunil*, 251, 257, 1062
- EMD-56551*, 1053
- EN-01*, 1062
- Enciprazine*, 1066
- Endixaprine*, 1057
- Eplivanserin*, 1059, 1060
- Eptapirone*, 1062
- Escitalopram*, 114, 200, *See Citalopram*
- Eslicarbazepine*, 251, 260
- Ethyl loflazepate**, 974, 976  
    *Synthesis*, 974, 975  
    *Use*, 976
- Etifoxine**, 1010, 1011  
    *Synthesis*, 1010  
    *Use*, 1011
- Etizolam**, 973  
    *Synthesis*, 973  
    *Use and PK*, 973
- Etoperidone**, 216  
    *Synthesis*, 216  
    *Use*, 216

- F-11440, 1062  
F-2692, 1052  
Farampator, 251, 257, 580, 583  
FCE-23884, 1057  
Fenobam, 1065  
FG-10571, 1052  
Flesinoxan, 1067  
**Fluoxetine**, 74, 75, 77, 114, 194, 195, 197, 1189  
    Synthesis, 194  
    Use, PK and Metabolism, 197  
**Flupentixol**, 376, 397, 491, 492, 523, 524, 525  
    Synthesis, 524  
    Use, PK and Metabolism, 524  
**Fluphenazine**, 376, 396, 403, 491, 492, 509, 510, 1014, 1015  
    Synthesis, 509, 1014, 1015  
    Use, PK and Metabolism, 510  
**Fluspirilene**, 491, 492, 530, 531  
    Synthesis, 531  
    Use, 531  
**Fluvoxamine**, 74, 75, 77, 114, 202, 203  
    Synthesis, 202  
    Use, PK and Metabolism, 203  
Folate, 98  
**GAD**, 651, 652, 659, 673, 676, 692, 693, 721, 738, 777, 778, 779, 780, 781, 782, 783, 784, 807, 817, 881, 883, 885, 886, 887, 888, 889, 902, 903, 904, 905, 910, 917, 926, 1029, 1032, 1038, See Generalized anxiety disorder  
Gedocarnil, 1052  
Gepirone, 129, 250, 259, 1065  
Gidazepam, 1061  
Girisopam, 1058  
Glemanserin, 1052  
Glucocorticoid receptor, 835  
Glucocorticoids, XXXV, 124, 838  
Glutamatergic targets, 128  
GPE, 251, 258  
GR, 23, 26, 124, 130, 669, 764, 765, 766, 835, 836, 838, 840, 845, 846, 847, 848, See Glucocorticoid receptor  
GSK-372475, 250, 255, 1193  
guanfacine, 1138, 1140, 1170, 1194  
GV-150013, 1060  
GW-150013, 1060  
GW-273293, 251, 257  
GW-597599, 1063  
GW-679769, 1064  
GW-823296, 251, 253, 1056  
GW-876008, 250, 253, 1056  
GYKI-51189, 1058  
GYKI-52322, 1051  
**Halazepam**, 993, 995  
    Synthesis, 993, 994  
    Use, 995  
**Haloperidol**, 77, 376, 397, 403, 404, 414, 491, 492, 511, 512, 513, 515  
    Synthesis, 512  
    Use, PK and Metabolism, 513  
Harmala, 114  
Hebephrenic schizophrenia, 301, 366  
HPA, XXXV, XXXVI, XLV, 23, 24, 25, 26, 27, 33, 123, 124, 149, 157, 159, 668, 670, 671, 672, 677, 685, 698, 699, 709, 711, 712, 716, 735, 763, 767, 774, 778, 779, 782, 784, 854, 860, 862, 883, See Hypothalamic–pituitary–adrenal axis  
**Hydroxyzine**, 1041, 1042  
    Synthesis, 1041, 1042  
    Use and PK, 1042  
**Hypothalamic–pituitary–adrenal axis**, XXXVI, 23, 67, 123, 668, 671, 711  
ICI-118551, 1065  
ICI-170809, 1058  
lfoxetine, 249, 254  
lloperidone, 579, 585  
**Imipramine**, 74, 75, 77, 79, 113, 175, 176, 917  
    Synthesis, 176  
    Use, PK and Metabolism, 176

- Inositol*, 98, 917  
*IP-456*, 1068  
*Ipsapirone*, 1066, 1067  
*Irindalone*, 1057, 1059  
*Isamoltan*, 1051  
***Isocarboxazid***, 114, 235  
     *Synthesis*, 235  
     *Use, PK and Metabolism*, 235  
*Isovaleramide*, 254  
*Itriglumide*, 1054  
*JNJ-19567470*, 131, 250, 253, 1056  
*Kava extract*, 1050  
*KC-9172*, 1051  
***Ketazolam***, 89, 991, 993  
     *Synthesis*, 992  
     *Use*, 993  
*Ketoconazole*, 77, 97  
*L-0068*, 1062  
*L-365260*, 1058  
*Ladasten*, 1062  
***Lamotrigine***, 246, 247, 580, 581, 586  
     *Synthesis*, 247  
     *Use, PK and Metabolism*, 247  
*LAX-101*, 130, 257  
*LAX-201*, 249, 255  
*Laxdale*, 249  
*Lesopitron*, 1059  
***Levomepromazine***, 376, 491, 492, 502  
     *Synthesis*, 502  
     *Use, PK and Metabolism*, 502  
*Levoprotiline*, 1068  
***Levosulpiride***, 491, 492, 526, 527, 542, 543  
     *Synthesis*, 542  
     *Use, PK and Metabolism*, 543  
*Levotofisopam*, 998, 1055  
*Licarbazepine*, 251, 259  
*Lisdexamphetamin*, 1194  
*Lisdexamphetamine*, 1192  
***Lithium***, 32, 94, 96, 112, 115, 239, 491, 492, 494  
     *Use and PK and Metabolism*, 239  
     *Use, PK and Metabolism*, 494  
*lobeline*, 1192  
*Lobeline*, 1193  
***Lofepramine***, 74, 113, 192  
     *Synthesis*, 192  
     *Use, PK and Metabolism*, 192  
*Lonasen*, 429  
***Lorazepam***, 89, 963, 964, 965  
     *Synthesis*, 963, 964  
     *Use, PK and Metabolism*, 964  
***Lormetazepam***, 89, 964, 965  
     *Synthesis*, 965  
     *Use, PK and Metabolism*, 965  
***Loxapine***, 491, 492, 534, 535  
     *Synthesis*, 534  
     *Use, PK and Metabolism*, 535  
*LU-21-098*, 1059  
*LU-21-098X*, 1057  
*LU-28-179 HCl*, 1056  
*Lu-31-130*, 580, 582  
*Lu-AA-21004*, 249, 252  
*Lu-AA-24530*, 251, 254  
*Lu-AA34893*, 1056  
*Lurasidone*, 579, 582  
*LY-2140023*, 580, 584  
*LY-277359*, 1068  
*LY-314582*, 1061  
*LY-354740*, 1061  
*LY-404039*, 580, 584  
*LY-544344*, 1055  
*MADD*, 784, 785. *See Mixed anxiety–depression disorder*  
*Major depressive disorder*, 57, 85. *See Depression*  
*Manic depressive disorder. See Bipolar disorder*

- MAOIs**, 22, 81, 82, 83, 84, 88, 92, 94, 100, 102, 111, 112, 113, 118, 131, 233, 237, 889, 897, 915, 1189, *See Monoamine oxidase inhibitors*
- Maprotiline**, 74, 79, 189  
*Synthesis*, 189  
*Use, PK and Metabolism*, 190
- MCH antagonists, 126
- MCI-242, 1065
- MDL-11939, 1052
- MDL-73005EF, 1052
- ME-3127, 1062
- Mebicar**, 1039  
*Synthesis*, 1039
- Mecamylamine, 1192
- Medazepam**, 954, 980, 982  
*Synthesis*, 980, 981, 982  
*Use and PK*, 982
- Medetomidine, 1057
- Medifoxamine, 251, 254
- Melitracen, 248
- Melperone**, 491, 1016  
*Synthesis*, 1016  
*Use, PK and Metabolism*, 1016
- MEM-1003, 251, 257
- MEM-3454, 580, 582
- Memory**  
*Categories*, 804  
*Cholecystokinin*, 850  
*Consolidation and emotions*, 834  
*Glutamate*, 852  
*Hippocampal dissociations*, 855  
*Neurobiology*, 831  
*Processes and mechanisms*, 803  
*Release of stress hormones*, 837, 845, 847  
*Relevance of Hippocampus*, 855, 857  
*Relevance of the amygdala*, 835, 836, 837, 843, 847  
*Retrieval*, 845  
*Steps*, 805  
*Storage*, 832  
*Temporal nature*, 805
- Meprobamate**, 1039, 1040  
*Synthesis*, 1040  
*Use, PK and Metabolism*, 1040
- metanicotine, 1192
- Metanicotine, 1193
- Metapramine, 248
- Methamphetamine**, 1184, 1185  
*Synthesis*, 1184  
*Use*, 1185
- Methamphetamine, 1184
- Methylphenidate**, 1134, 1136, 1185, 1187  
*Synthesis*, 1185  
*Use, PK and Metabolism*, 1187
- Methylphenidate, 1185
- Metirapone, 97
- Mianserin, 74, 75, 79, 87, 229, 248
- Midazolam**, 89, 965, 968  
*Metabolism*, 968  
*Synthesis*, 966, 967  
*Use and PK*, 968
- Mifepristone**, 581, 586, 1026, 1027  
*Synthesis*, 1027
- Milnacipran**, 220, 221  
*Synthesis*, 220  
*Use and Metabolism*, 221
- Miraxion, 130, 251, 257
- Mirisetron, 1053
- Mirtazapine**, 74, 87, 229, 230  
*Synthesis*, 230  
*Use*, 230
- Mixed amphetamine salts, 1136, 1183
- MJ-13805, 1065
- MKC-242, 411, 1065
- MN-305, 1065

- Moclobemide**, 74, 75, 114, 237, 238, 898, 999, 1000  
 Synthesis, 237, 999, 1001  
 Use, PK and Metabolism, 237
- Modafinil, 580, 585, 1140, 1192
- Monoamine oxidase inhibitors**, XL, 81, 112, 113, 114, 116, 233, 999  
 Adverse effects, 83  
 Indications, 83  
 Interactions, 82  
 Intoxication, 83  
 Mechanism of action, 82  
 Non-selective, 233  
 Pharmacokinetics, 82  
 Precautions, 82  
 Type A, 237
- Mosapramine**, 491, 492, 545, 546  
 Synthesis, 545  
 Use, PK and Metabolism, 546
- MPV-785, 1057
- NAE-086, 1053
- NBI-34041, 26, 1055
- ND-7001, 251, 253, 1056
- Neboglamine, 250, 253, 580, 582
- Nefazodone**, 77, 217, 218  
 Synthesis, 217  
 Use, PK and Metabolism, 218
- Nemifitide, 130, 251, 258
- Nemonapride**, 491, 492, 547, 548  
 Synthesis, 547  
 Use, 548
- NEO-339, 1192
- Nerisopam, 1051
- Neurotrophins, 126
- NGD-91-1, 1053
- NGD-91-2, 1056
- NGD-91-3, 1062
- NGI-101, 1064
- NGI-221, 1192
- NK1 antagonists, 125
- NKP-608, 1061
- Noradrenaline and specific serotonergic antidepressants**, 229
- Noradrenaline reuptake inhibitors**, XL, 87, 112, 114, 231
- Norclozapine, 584  
 norclozapine/N-desmethylozapine, 580
- Nordazepam**, 990, 991, 993  
 Synthesis, 991  
 Use, PK and Metabolism, 991
- Nortriptyline**, 113, 182  
 Synthesis, 182  
 Use, PK and Metabolism, 182
- NPS-1776, 251, 254
- NRP-104, 1192, 1194
- NS-2359, 255, 1193
- NS-2710, 1062
- Ocaperidone, 579, 582
- OCD**, 194, 210, 652, 653, 655, 673, 691, 692, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 737, 740, 741, 807, 814, 820, 881, 890, 891, 892, 914, 915, 916, 917, See Obsessive-compulsive disorder
- O-Desmethylenlafaxine, 1069
- Olanzapine**, 377, 403, 404, 430, 491, 493, 559, 560, 563  
 Synthesis, 559  
 Use, PK and Metabolism, 560
- Omega-3 fatty acids, 99
- Ondansetron, 580, 583
- ONO-2333MS, 26, 250, 253, 1056
- OPC-14523, 130, 254
- Opipramol**, 179  
 Synthesis, 179  
 Use, 179
- ORG 24448, 429
- ORG 5222, 429
- ORG-25935, 580, 581
- ORG-33062, 1065

- ORG-34517, 251, 257
- Osemozotan, 1065
- Oxaprotiline, 250, 259
- Oxazepam**, 89, 978, 979  
Synthesis, 978, 979  
Use and PK, 979
- Oxprenolol**, 1024, 1026  
Synthesis, 1024, 1025  
Use, PK and Metabolism, 1026
- Oxycodone, 98
- Oxymorphone, 98
- Pagoclone, 1068
- Paliperidone, 579, 585, 586
- Panadiplon, 1052
- Paranoid schizophrenia, 301, 367
- Paroxetine**, 74, 75, 77, 114, 206, 208, 1190  
Synthesis, 206  
Use, PK and Metabolism, 208
- Pazinaclone, 1067
- PD**, 721, See *Panic disorder*
- PD-134308, 1060
- PD-216948, 1055
- Pemoline, 1166, 1183
- Periciazine**, 491, 492, 519, 520  
Synthesis, 519  
Use, 520
- Perospirone**, 491, 493, 570  
Synthesis, 570  
Use, PK and Metabolism, 570
- Perphenazine**, 376, 397, 491, 492, 503, 504  
Synthesis, 504  
Use, PK and Metabolism, 504
- PF-00184562, 580, 582
- PFC, 15, 29, 30, 305, 310, 312, 313, 314, 315, 318, 320, 321, 324, 325, 389, 411, 415, 417, 420, 421, 426, 430, 449, 453, 455, 457, 458, 461, 462, 464, 465, 466, 467, 729, 835, 843, 847, 848, 849, 850, 852, 856, See *Prefrontal cortex*
- PH-94B, 1063
- Phenelzine**, 74, 75, 114, 234, 917  
Synthesis, 234  
Use, PK and Metabolism, 234
- Phosphodiesterase inhibitors, 128
- Photostimulation, 100
- Piberaline, 251, 257
- Pikamilone, 1059
- Pimozide**, 376, 397, 491, 492, 528, 529  
Synthesis, 529  
Use, PK and Metabolism, 529
- Pindolol, 98
- Pipotiazine**, 491, 492, 533, 534  
Synthesis, 533  
Use, PK and Metabolism, 534
- Piricapiron, 1061
- Pramipexol, 98
- Pramipexole, 250, 255
- Prazepam**, 983  
Synthesis, 983, 984
- Prefrontal cortex, 843
- Pregabalin**, 1032, 1038  
Synthesis, 1033, 1034, 1035, 1036, 1037  
Use, 1038
- Procaine, 252, 261
- Prochlorperazine**, 397, 491, 492, 499, 500  
Synthesis, 500  
Use, PK and Metabolism, 500
- Promazine**, 491, 492, 501  
Synthesis, 501  
Use and PK, 501
- Propranolol**, 77, 1021, 1023  
Synthesis, 1021, 1022, 1023  
Use, PK and Metabolism, 1023
- Protriptyline**, 113, 186, 187  
Synthesis, 186  
Use, PK and Metabolism, 186
- PRX-00023, 129, 250, 258, 1068, 1192, 1194
- Psychosocial treatments, 101, 377, 1142

*Psychostimulants*, 97, 1134, 1166, 1183

*Psychosurgery*, 101

**PTSD**, 210, 653, 654, 655, 659, 668, 671, 687, 688, 689, 709, 710, 711, 712, 713, 714, 715, 716, 717, 736, 738, 761, 767, 768, 769, 770, 771, 772, 774, 807, 816, 817, 819, 820, 881, 885, 892, 911, 912, 913, 917, *See Panic disorder*

PW-4112, 251, 260

PW-4123, 581, 582

**Quetiapine**, 261, 377, 403, 404, 491, 493, 564, 565

*Synthesis*, 564

*Use, PK and Metabolism*, 565

*Quinupramine*, 248

R-1204, 1055

R-1678, 581, 582

R-228060, 257

R-55667, 1066

R-56413, 1057

R-673, 1064

*Radafaxine*, 130, 250, 255

**Reboxetine**, 74, 87, 231, 232

*Synthesis*, 231

*Use, PK and Metabolism*, 232

**Remoxipride**, 403, 491, 492, 544

*Synthesis*, 544

*Use, PK and Metabolism*, 544

*Repetitive transcranial magnetic stimulation*, 100

*Residual schizophrenia*, 301, 367

RG-2417, 1064

RGH-188, 250, 252, 580, 583

**Ricasetron**, 1058, 1060

**Rilmazafone**, 1006, 1007

*Metabolism*, 1007, 1008

*Synthesis*, 1006, 1007

*Use and PK*, 1007

**Risperidone**, 77, 377, 403, 404, 491, 493, 555, 556, 557

*Synthesis*, 556

*Use, PK and Metabolism*, 557

*Ritanserlin*, 408, 1066

Ro-16-6028, 1066

Ro-16-6028/000, 1066

Ro-46-2153, 1054

Ro-48-6791, 1054

Ro-48-8684, 1054

Ro-67-5930, 1063

*Rolipram*, 251

*Romergoline*, 1057

RP-31264, 1065

RP-59037, 1068

RP-62955, 1068

Ru-32698, 1058

RWJ-51204, 1062

SJ-DMZ, 1055

S-15535, 1053

S-16924, 1061

S-20098, 261

S-20499, 1060

SA-4503, 251, 256

*S-adenosyl-methionine*, 98

**Sapropterin**, 1011

*Synthesis*, 1011, 1012

*Saredutant*, 129, 251, 260, 1068

*Saripidem*, 1059

SAX-187, 1056

SB-163090, 250, 252

SB-243213, 1054

SB-247853, 250, 252, 1054

SB-723620, 1055

SB-773812, 580, 583

SC-48274, 1060

**Schizophrenia**

- Affective symptoms, 358
- Attention deficit, 351
- Brain pathology, 308
- Cellular abnormalities, 313
- Classification, 300
- Cognitive deficit, 305, 347, 350, 356
- Course, 307
- Diagnosis, 300
- Dopaminergic hypothesis, 318, 369, 391
- Epidemiology, 306, 341, 360
- Etiology, 367
- Executive function, 354
- GABAergic hypothesis, 325
- Genetics, 368
- Glutamatergic hypothesis, 321, 370
- Infectious hypothesis, 372
- Introduction, 299, 335, 336
- Language disorders, 355
- Memory alterations, 352
- Negative symptoms, 345
- Neuroendocrine hypothesis, 372
- Neuroimaging, 309, 371
- Neurophysiology, 371, 391, 450
- Onset, 365
- Pathogenesis, 316
- Positive symptoms, 342
- Prognosis, 373
- Psychosocial factors, 372
- Risk factors, 361
- Semiology, 341
- Serotonergic hypothesis, 320, 370
- States, 366
- Suicide risk, 360, 363, 364
- SEB-324, 1059
- SEC-579, 1053
- Secretin, 429
- Seganserin, 1057
- Selanc, 1065
- Selective serotonin reuptake inhibitors**, XLIV, 84, 112, 114, 193, 198, 917
  - Adverse events, 85
  - Indications, 85
  - Management, 84
  - Pharmacokinetics, 84
  - Serotonergic syndrome, 85
- Selegiline**, 114, 252, 261
- Selfotel, 1067
- SEP-174559, 1055
- SEP-225289, 130, 250, 252
- Serazapine, 1059
- Serotonin and noradrenaline reuptake inhibitors**, XLIV, 86, 112, 115, 220
  - Adverse events, 86
  - Indications, 86
- Sertindole**, 377, 403, 491, 493, 573, 574
  - Synthesis, 573
  - Use, PK and Metabolism, 574
- Sertraline**, 74, 75, 77, 114, 210, 211
  - Synthesis, 210
  - Use, PK and Metabolism, 211
- Setiptiline, 248
- SGS-518, 580, 583
- SGS-742, 1192, 1193
- SH-530, 1052
- Simple schizophrenia, 301, 367
- Siramesine, 1056
- SL-65.1498, 1063
- SL-651498, 1063
- SL-85.0274, 1059
- Sleep deprivation, 27, 100
- SLV-308, 259
- SLV-313, 583
- SLV-314, 249, 252, 580, 581
- SNRIs**, 22, 86, 112, 115, 118, 131, 146, 220,
  - See Serotonin and noradrenaline reuptake inhibitors

- SP**, 125, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, *See Social phobia*
- SPD-465**, 1192, 1194
- SPD-503**, 1192, 1194
- SPPI-339**, 1192
- SR-149415**, 1063
- SR-41378**, 1057
- SR-46349B**, 1060
- SR-46349C**, 1059
- SR-48965**, 1068
- SR-48968**, 1068
- SR-489686**, 1068
- SR-58611**, 251, 260, 1068
- SR-58611A**, 1068
- SSR-125543**, 250, 253, 1055
- SSR-125543A**, 26, 1055
- SSR-149415**, 251, 256, 1063
- SSR-240600**, 1063
- SSR-240600C**, 1063
- SSR-411298**, 1055
- SSR-504734**, 580, 581
- SSRIs**, 11, 19, 22, 83, 84, 85, 92, 99, 102, 111, 112, 114, 115, 117, 118, 119, 120, 126, 129, 131, 149, 151, 152, 173, 194, 195, 233, 249, 430, 508, 677, 713, 714, 720, 736, 883, 889, 892, 897, 898, 899, 902, 903, 906, 907, 908, 909, 910, 911, 912, 914, 915, 917, 933, 1139, *See Selective serotonin reuptake inhibitors*
- St. John's Wort extract**, 122, 251, 260
- Sulpiride**, 403, 423, 491, 492, 526, 527  
*Synthesis*, 527  
*Use, PK and Metabolism*, 527
- Sultopride**, 491, 492, 536, 537  
*Synthesis*, 536  
*Use and PK*, 537
- Sunepitron**, 1068
- Suriclone**, 1065
- SX-5216**, 1062
- Talaglumetad**, 1055
- Talnetant**, 429, 580, 583
- Tandospirone**, 249, 491, 492, 548, 1003, 1006  
*Synthesis*, 548, 1003, 1004, 1005  
*Use*, 548, 1006
- TC-5231**, 1192
- TCAs**, 22, 78, 79, 80, 83, 84, 85, 99, 100, 111, 112, 113, 115, 124, 129, 131, 147, 149, 151, 159, 173, 176, 178, 181, 182, 185, 186, 188, 190, 192, 193, 194, 197, 201, 203, 208, 211, 215, 216, 218, 220, 231, 233, 234, 239, 243, 245, 248, 508, 579, 897, 898, 899, 903, 909, 910, 912, 1183, 1184, *See Tricyclic antidepressants*
- Teniloxazine**, 251, 260
- Tetrabamate**, 1009  
*Synthesis*, 1009, 1010
- Thioridazine**, 397, 491, 492, 506, 507  
*Synthesis*, 506  
*Use, PK and Metabolism*, 506
- Thiothixene**, 397, 491, 492, 520, 522  
*Synthesis*, 520  
*Use, PK and Metabolism*, 520
- Tiagabine**, 1029, 1031  
*Synthesis*, 1030, 1031  
*Use, PK and Metabolism*, 1031
- Tianeptine**, 248, 1017, 1018  
*Synthesis*, 1017, 1018  
*Use, PK and Metabolism*, 1018
- Tiapride**, 491, 492, 538, 539  
*Synthesis*, 538  
*Use, PK and Metabolism*, 539
- Tofizopam**, 998  
*Synthesis*, 998, 999  
*Use*, 998
- Tolcapone**, 429
- Toloxatone**, 238  
*Synthesis*, 238  
*Use, PK and Metabolism*, 238
- TP-7**, 1065
- TPA-023**, 1054

- Tranlycypromine**, 74, 82, 114, 236  
    Synthesis, 236  
    Use, PK and Metabolism, 236
- Trazodone**, 75, 88, 114, 214, 215  
    Synthesis, 214  
    Use, PK and Metabolism, 214
- Tricyclic antidepressants**, 78, 112, 173, 915, 1138  
    Adverse events, 80  
    Indications, 80  
    Intoxication, 81  
    Mechanism of action, 78  
    Pharmacokinetics, 79  
    Precautions, 79  
    Prescription, 80
- Trifluoperazine**, 397, 491, 492, 508, 509, 1012, 1013  
    Synthesis, 508, 1012  
    Use and PK, 509, 1013
- Triflupromazine**, 491, 492, 505  
    Synthesis, 505  
    Use, PK and Metabolism, 505
- Triiodothyronine, 96
- Trimipramine**, 113, 178  
    Synthesis, 178  
    Use and PK, 178
- Tryptophan, 19, 97
- TS-041, 26, 131, 1056
- TVX-Q-7821, 1066, 1067
- Typical antipsychotics**, 98, 396, 403, 492, 494  
    Dopamine receptors, 398  
    Side-effects, 400
- U-41123, 1066
- U-78875, 1052
- U-93385, 1053
- Umespirone, 1051
- Unipolar depressive disorder. *See* Depression
- Uridine, 251, 254, 1064
- Vabicaserin, 580, 583
- Vagus nerve stimulation, 100
- Valnoctamide**, 1047, 1050  
    Synthesis, 1047, 1048, 1049  
    Use and PK, 1050
- Valproic acid, 244, *See* Divalproex
- Vasopressin receptor antagonists, 124
- VEC-162, 251, 257
- Venlafaxine**, 74, 77, 86, 223, 224, 917  
    Synthesis, 223  
    Use, PK and Metabolism, 224
- Veralipride**, 491, 492, 540  
    Synthesis, 540  
    Use and PK, 540
- Vesipitant, 251
- Vestipitant, 130, 251, 256, 1063
- Vilazodone, 250, 258
- Viloxazine**, 245  
    Synthesis, 245  
    Use, PK and Metabolism, 245
- Viqualine, 249, 258
- Virucort, 252, 261
- VPI-013, 130, 250, 255
- WAY-100289, 1053
- WAY-100579, 1053
- WAY-181187, 1056
- WAY-SEB-324, 1059
- WAY-SEC-579, 1053
- WY-45233, 1069
- Wy-47846, 1058
- Wy-48624, 1066
- Wy-50324, 1059
- XBD-173, 1064
- XY-2401, 580, 582
- Y-22990, 1052
- Y-23684, 1067
- YKP-10A, 130, 251, 257
- YKP-1358, 579, 581

YKP-581, 251, 254

Zalospirone, 1058

Zatosetron, 1068

**Ziprasidone**, 377, 403, 404, 491, 493, 566, 567, 570

*Synthesis*, 566

*Use, PK and Metabolism*, 566

ZK-91296, 1057

ZK-93423, 1051

ZM-170809, 1058

**Zotepine**, 491, 493, 553, 555

*Synthesis*, 554

*Use, PK and Metabolism*, 555

**Zuclopenthixol**, 491, 492, 516

*Synthesis*, 516

*Use, PK and Metabolism*, 516

$\alpha_2$  antagonists, 118